10-Q quarterly report · filed Nov 6, 2026

Protara Therapeutics, Inc. (TARA) Q3 2026 10-Q Quarterly Report

Short answer

Protara Therapeutics, Inc. (TARA) filed its Q3 2026 10-Q quarterly report on Nov 6, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$22M
−63.6% YoY · −0.1% QoQ
EPS (diluted)
−$0.34
−9.7% YoY · +5.6% QoQ

Source: XBRL data from the Protara Therapeutics, Inc. (TARA) Q3 2026 10-Q on SEC EDGAR. USD.

Protara Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, with no product sales since inception
  • Operating margin not meaningful: operating loss $23.2M vs $14.8M YoY
  • R&D highest spend, $16.8M vs $9.6M, led by NMIBC expenses of $6.9M
  • Cash and securities $143.1M vs $197.9M at December 31, 2025; operating cash use $55.2M
  • ADVANCED-2 enrollment expected complete by end of 2026; interim THRIVE-3 results expected fourth quarter 2026

Risk Factors

  • No material changes to risk factors disclosed in the December 31, 2025 Form 10-K
  • Carried-forward risks remain applicable across regulatory, operational, competitive, and financial categories

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Protara Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.